The disclosure is directed to methods for preventing or treating cardiovascular disease and kidney dysfunction in certain patient populations which involve determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject, and performing various therapeutic interventions based on the suPAR level in the sample.